180 Life Sciences

👥 6 employees💰 Last funded Jul 2021
Biotechnology Research🌐 180lifesciences.com
Website LinkedIn
180 Life Sciences Corp. (NASDAQ: ATNF) is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The Company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The Company’s primary platform is a novel program to treat fibrosis using anti-TNF (tumor necrosis factor).
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in 180 Life Sciences?
180 Life Sciences has 1 investors on record on gritt.io.
When did 180 Life Sciences last raise funding?
The most recent investment in 180 Life Sciences recorded on gritt.io was in July 2021.
What industry is 180 Life Sciences in?
180 Life Sciences operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.